Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe Ulcerative Colitis

Sandborn, William J.; Assche, Gert Van; Reinisch, Walter; Colombel, Jean–Frédéric; D’Haens, Geert R.; Wolf, Douglas C.; Kron, Martina; Tighe, Mary; Lazar, Andreas; Thakkar, Roopal

doi:10.1097/00054725-201112002-00008

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, another recently published study demonstrated that oxidative stress during active inflammation permanently impaired the integrity of DNA in colonic smooth muscle cells and caused persistent damage in the expression of calcium channels 48. This phenomenon occurred even after inflammation had subsided, and could explain the smooth muscle dysfunction and persistence of symptoms even in patients with quiescent inflammatory bowel disease (IBD) and healed mucosae 49…”

Section: Dysmotilitymentioning

confidence: 99%

Ulcerative Colitis as A Progressive Disease: The Forgotten Evidence

Torres

Billioud

Sachar

et al. 2012

Inflammatory Bowel Diseases

Self Cite

232

145

View full text Add to dashboard Cite

In the management of Crohn's disease, earlier aggressive treatment is becoming accepted as a strategy to prevent or retard progression to irreversible bowel damage. It is not yet clear, however, if this same concept should be applied to ulcerative colitis. Hence, we review herein the long-term structural and functional consequences of this latter disease. Disease progression in ulcerative colitis takes six principal forms: proximal extension, stricturing, pseudopolyposis, dysmotility, anorectal dysfunction, and impaired permeability. The precise incidence of these complications and the ability of earlier, more aggressive treatment to prevent them have yet to be determined.

show abstract

Section: Dysmotilitymentioning

confidence: 99%

Ulcerative Colitis as A Progressive Disease: The Forgotten Evidence

Torres

Billioud

Sachar

et al. 2012

Inflammatory Bowel Diseases

Self Cite

232

145

View full text Add to dashboard Cite

show abstract

“…Recently, the results of an induction and maintenance study were presented. 36 In this study 494 UC patients (Mayo score 6–12, endoscopic subscore 2–3 points) were randomized to placebo or adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg eow starting on week 4. Co-primary endpoints were clinical remission at week 8 and clinical remission at week 52.…”

Section: Adalimumab In Ulcerative Colitismentioning

confidence: 99%

Update on the management of inflammatory bowel disease: specific role of adalimumab

Guidi¹,

Pugliese²,

Armuzzi³

2011

CEG

View full text Add to dashboard Cite

Anti-tumor necrosis factor alpha (TNF-α) medications are a class of biologics employed in the treatment of patients with inflammatory bowel disease (IBD). Adalimumab is the first fully human monoclonal immunoglobulin directed against TNF-α, which binds with high affinity and specificity to membrane and soluble TNF. Adalimumab administered subcutaneously has demonstrated efficacy in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and severe chronic psoriasis. Studies have shown that adalimumab is effective for inducing and maintaining remission of moderate-to-severe active Crohn’s disease (CD) patients at an induction dose of 160/80 mg (week 0 and 2) and at a maintenance dose of 40 mg every other week. The efficacy of adalimumab as a second-line therapy has also been documented for patients with loss of response or intolerance to infliximab. Adalimumab is also superior to placebo for inducing and maintaining complete perianal fistula closure. It also seems effective for reducing extraintestinal manifestations. The safety profile is similar to that of other anti-TNF therapy in CD patients, with lower immunogenicity and rate of adverse injection reactions than infliximab. Adalimumab is not approved for the treatment of ulcerative colitis (UC). Recently, however, the results of the first randomized, controlled trial on adalimumab for UC showed that adalimumab at 160/80 mg induction dose was safe and effective for inducing remission and clinical response after 8 weeks in patients with moderately-to-severely active UC failing treatment with corticosteroids and/or immunosuppressants. More data are necessary to clarify the therapeutic role of adalimumab in UC. This review of the literature summarizes available data on the efficacy and safety profile adalimumab in patients with IBD.

show abstract

“…Indeed, the second extended (52‐week) open‐label phase of this trial has been completed, and results indicate that with dose escalation to 40 mg ADA every week following the initial 8‐week induction, a remission rate of 29.5% was achieved at 52 weeks 6. Similarly, in the second pivotal double‐blind trial, significant increases in clinical response and mucosal healing were also observed at 52 weeks compared to placebo 7. Overall, it appears that one of the main issues with this trial, i.e., treatment duration, is being resolved, even though dose would require better investigation since in the second pivotal trial only a very modest effect of ADA 160/80 in remission rate was confirmed.…”

Section: Commentarymentioning

confidence: 94%

Adalimumab for ulcerative colitis: A little is better than none?

Danese

2012

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe Ulcerative Colitis

Cited by 7 publications

References 0 publications

Ulcerative Colitis as A Progressive Disease: The Forgotten Evidence

Ulcerative Colitis as A Progressive Disease: The Forgotten Evidence

Update on the management of inflammatory bowel disease: specific role of adalimumab

Adalimumab for ulcerative colitis: A little is better than none?

Contact Info

Product

Resources

About